tDCS for Social Media Addiction

The goal of this clinical trial is to learn whether transcranial direct current stimulation (tDCS), a non-invasive brain stimulation, can reduce "craving" and problematic levels of social media/internet use in university students. The main questions it aims to answer are: * Does active tDCS reduce craving to use social media during the intervention period compared with sham stimulation and no stimulation? * Does active tDCS reduce internet/social media addiction severity (measured with the Internet Addiction Test, IAT) compared with sham stimulation and no stimulation, and are any effects still present at follow-up? Researchers will compare three groups-active tDCS, sham tDCS (a simulation where stimulation is stopped after the first seconds), and a control group (no stimulation)-to see whether changes are due to tDCS rather than placebo effects or time. Participants will: * Complete an initial screening and baseline questionnaires (a sociodemographic questionnaire and the IAT). * Be randomly assigned to one of three groups: active tDCS, sham tDCS, or control (no stimulation). * Complete the IAT again after the intervention and again about 5 weeks later (follow-up), along with questions about social media use habits. During intervention, participants in active tDCS and sham tDCS will: * Attend 10 sessions over 2 consecutive weeks (Monday-Friday), with each session lasting about 30 minutes; mobile phone use is not allowed during sessions. * Rate craving on a Visual Analogue Scale (VAS) at the start and end of each session. This study will be conducted with university students in the Greater Lisbon area and will follow double-blind procedures for the active vs sham conditions (participants and researchers will not know the assigned condition until the end of the study).

NCT Number	NCT07410104
Lead Sponsor	Egas Moniz - Cooperativa de Ensino Superior, CRL
Conditions	Social Media Addiction, Craving to Use Social Media, Craving, Internet Addiction
Enrollment	60 participants
Start Date	2026-03
Primary Completion	2026-03 (estimated)
Study Completion	2026-09 (estimated)
Updated on ClinicalTrials.gov	2026-02-20